Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors

The development of CDC25 phosphatase inhibitors is an interesting approach toward new antitumor agents, as CDC25 play keyroles in cell-cycle regulation and are overexpressed in numerous cancers. We previously reported a novel compound belonging to the thiazolopyrimidine family that inhibits CDC25 activity with an IC50 value of 13 µM and displays cytotoxic properties against HeLa cells. Structural modifications were subsequently conducted on this new pharmacophore which led to a library of 45 thiazolopyrimidines

 

Stephanie Kolb, Odile Mondesert, Mary-Lorène Goddard, Denis Jullien, Bruno O. Villoutreix, Bernard Ducommun, Christiane Garbay,
April 1, 2009
Learn More
LinkedIn